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Septic shock is characterized by increased vascular permeability and hypotension despite increased cardiac 
output. Numerous vasoactive cytokines are upregulated during sepsis, including angiopoietin 2 (ANG2), 
which increases vascular permeability. Here we report that mice engineered to inducibly overexpress ANG2 in 
the endothelium developed sepsis-like hemodynamic alterations, including systemic hypotension, increased 
cardiac output, and dilatory cardiomyopathy. Conversely, mice with cardiomyocyte-restricted ANG2 overex-
pression failed to develop hemodynamic alterations. Interestingly, the hemodynamic alterations associated 
with endothelial-specific overexpression of ANG2 and the loss of capillary-associated pericytes were reversed 
by intravenous injections of adeno-associated viruses (AAVs) transducing cDNA for angiopoietin 1, a TIE2 
ligand that antagonizes ANG2, or AAVs encoding PDGFB, a chemoattractant for pericytes. To confirm the role 
of ANG2 in sepsis, we i.p. injected LPS into C57BL/6J mice, which rapidly developed hypotension, acute peri-
cyte loss, and increased vascular permeability. Importantly, ANG2 antibody treatment attenuated LPS-induced 
hemodynamic alterations and reduced the mortality rate at 36 hours from 95% to 61%. These data indicate that 
ANG2-mediated microvascular disintegration contributes to septic shock and that inhibition of the ANG2/
TIE2 interaction during sepsis is a potential therapeutic target.
Introduction
Constitutive ablation of the TIE2 receptor impairs vascular integ-
rity during a midgestional stage of development (1, 2). Interest-
ingly, these observations have been phenocopied by a heart-re-
stricted ablation of the angiopoietin 1 (Ang1) gene (3). Loss of 
ANG1 (4) as well as endothelial overexpression of angiopoietin 
2 (ANG2), antagonizing TIE2 (5), both induce vessel destabiliza-
tion during development. Recent evidence suggests that increased 
destabilization and vascular regression in adult organisms occur 
by ANG2/TIE2–mediated phosphorylation of Ser910 of focal 
adhesion kinase (6, 7). ANG2 was shown to be upregulated in a 
variety of disease entities linked to systemic inflammation, hyper-
permeability, and vessel destabilization: renal failure in patients 
with multiorgan disease, pulmonary leakiness leading to adult 
respiratory distress syndrome, and sepsis development have all 
been linked to increased ANG2 levels circulating in the blood 
(8–11). These findings raise the possibility that excess ANG2 crit-
ically affects the cardiovascular homeostasis during sepsis by dis-
turbing the microvascular architecture, potentially by impairing 
endothelial/pericyte interaction. It has been shown previously that 
vascular permeability is controlled by pericytes in the blood-brain 
barrier (12). However, a role of pericytes controlling vascular integ-
rity and blood pressure homeostasis during systemic inflamma-
tory processes has not been studied.
In this paper, we investigated whether ANG2, when inducibly 
overexpressed in the endothelium or cardiomyocytes of mice, 
induces hyperpermeability, hypotension, and pericyte loss in vivo. 
Finally, we also investigated whether ANG2 inhibition is beneficial 
for pericyte investment and hemodynamic stability in a murine 
model of endotoxemia.
Results
First, we generated a mouse strain in which moderate human 
ANG2 (hANG2) expression was induced in endothelial cells in 
the absence of tetracyclines and could be switched off by the oral 
application of doxycycline (TIE2-tTA/TRE-hANG2 mice, referred 
to herein as EC-ANG2-on mice; Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI66549DS1). In the EC-ANG2-on state, mice displayed increased 
body weight (Supplemental Figure 2), edema (Figure 1A), and 
increased vascular diameters (Figure 1B). Moreover, permeabil-
ity of ear vessels for the small molecule tracer TRITC-dextrane 
(4 kDa) was enhanced in EC-ANG2-on mice (Figure 1, C and D).
The rise in permeability conveyed by ANG2 (13) was previ-
ously attributed to its antagonism toward ANG1, a TIE2 ligand 
secreted by pericytes and promoting endothelial integrity (4, 
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Figure 1
Endothelial ANG2 overexpression induces pericyte loss and increased 
vascular permeability. (A) Inducible endothelial ANG2-overexpress-
ing mice (EC-ANG2-on mice) develop enlarged lips (red arrow), (B) 
enlarged ear vessels (scale bar: 200 μm), and (C and D) increased 
permeability for 4-kDa TRITC-dextran (scale bar: 50 μm; n = 4). (E–G) 
Cardiac capillary density (PECAM-1 staining) and pericyte coverage 
(NG2 staining) are decreased in EC-ANG2-on mice (n = 5 for EC-Con-
trol and EC-ANG2-on, n = 4 for EC-ANG2-off). Scale bar: 50 μm (E); 
5 μm (F). *P < 0.05, **P < 0.001.
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14–16). Moreover, pericyte loss itself causes increased permea-
bility in distinct vascular beds, e.g., the blood-brain barrier (12). 
Therefore, we investigated the possibility of pericyte loss in the 
hyperpermeable EC-ANG2-on state. Indeed, EC-ANG2-on hearts 
revealed a significant loss of pericytes, which coincided with lower 
capillary counts (Figure 1, E–G). Of particular note, doxycycline 
was applied at week 12 to switch off ANG2 formation, which was 
present since birth. This protocol entirely prevented the pericyte 
loss and capillary rarefaction at the 24-week time point (Figure 
1, E–G). Moreover, recombinant adeno-associated virus ANG2 
(rAAV.ANG2) transduction reduced the number of mural cells in 
the XLacZ4 mouse, which expresses β-galactosidase in mural cells 
(Supplemental Figure 2, A–C, and ref. 17).
We next analyzed the cardiovascular sequelae of the observed 
microvascular disturbance. Mean arterial pressure, obtained 
noninvasively by repetitive tail artery cuff measurements, 
decreased over time in the EC-ANG2-on mice (93 ± 3 mmHg at 
12 weeks and 85 ± 3 mmHg at 24 weeks), significantly differing 
from that of controls at 24 weeks (101 ± 2 and 100 ± 2 mmHg, 
respectively, P < 0.05 at 24 weeks; Figure 2A). Consistently, LV 
developed pressure (Figure 2B) was significantly lower over a 
broad range of norepinephrine stimuli (from 10 to 100 ng boli), 
when assessed invasively by a pressure-tip catheter. The failure 
to mount a normal systolic blood pressure level was blunted by 
doxycycline-mediated inhibition of the previously active hANG2 
expression at 12 weeks and until 24 weeks of age. In order to 
Figure 2
Endothelial ANG2 overexpression leads to LV dysfunction and sys-
temic hypotension, while increasing cardiac output. (A) 24-week-
old EC-ANG2-on mice develop systemic hypotension (n = 18 for 
EC-Control, n = 12 for EC-ANG2-on) and (B) decreased LV devel-
oped pressure (LVdP) at rest and under -adrenergic stimulation 
(norepinephrine; n = 18 for EC-Control, n = 10 for EC-ANG2-on, 
n = 5 for EC-ANG2-off). MAP, mean arterial pressure. (C) Whereas 
LV end-diastolic pressure (LVEDP) is unaffected, (D) cardiac out-
put is increased in EC-ANG2-on mice (n = 7 per group). (E and F) 
The LV end-diastolic diameter (LVEDD) is dilated in EC-ANG2-on 
mice (n = 12) when compared with the control group (n = 18) or 
the EC-ANG2-off group (n = 7, hANG2 switched off at 12 weeks 
of age). (G) HW/BW ratios are elevated in EC-ANG2-on mice 
(n = 12) when compared with those in control mice (n = 18) but not 
EC-ANG2-off mice (n = 7). (H) Masson Trichrome staining revealed 
increased regional fibrosis in EC-ANG2-on hearts when compared 
with EC-ANG2-off hearts. Scale bars: 1,000 μm (Lens); 200 μm (10); 
50 μm (40). *P < 0.05 vs. EC-Control, **P < 0.001 vs. EC-Control, 
#P < 0.001 vs. EC-Control and EC-ANG2-off.
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distinguish between a systolic pump failure of the heart and a 
hypercirculatory state due to peripheral resistance loss, we ana-
lyzed LV end-diastolic pressure and cardiac output. Of note, LV 
end-diastolic pressure did not differ among control hearts as 
well as EC-ANG2-on hearts and hearts of mice with endothelial 
ANG2 overexpression switched off (EC-ANG2-off mice) (Figure 
2C). In contrast, cardiac output was significantly increased in the 
EC-ANG2-on mice (Figure 2D).
Reduced peripheral resistance and increased cardiac output 
are indicative of a hypercirculatory state, which leads to altered 
cardiac morphology. From 12 to 24 weeks of age EC-ANG2-on 
hearts displayed a progressive dilation of LV end-diastolic diam-
eters (Figure 2, E and F). Switching off ANG2 at the 12-week 
time point prevented a further LV end-diastolic diameter 
increase over time (Figure 2F). Moreover, an increased heart 
weight to body weight (HW/BW) ratio indicated a gain of heart 
muscle mass in the EC-ANG2-on state, when compared with 
that of control hearts (Figure 2G). EC-ANG2-off hearts were 
indistinguishable from control hearts and displayed a strong 
trend toward a lower HW/BW ratio compared with EC-ANG2-on 
hearts (P = 0.07; Figure 2G). Histologically, fibrosis was found 
in a patchy fashion in EC-ANG2-on hearts (Figure 2H and 
Supplemental Figure 2E) but neither in control hearts nor in 
EC-ANG2-off hearts. Taken together, pan-endothelial overex-
pression of ANG2 induces increased microvascular permeability 
and pericyte loss, associated with hypotensive hypercirculation 
and pathological cardiac hypertrophy.
We next asked whether the cardiac phenotype was caused by 
local, heart-specific or systemic, remote microvascular alterations. 
Therefore, we assessed the phenotype of a cardiomyocyte-re-
stricted ANG2 overexpression (CM-ANG2-on) by using α-MHC–
restricted expression of tTA. Of note, although heart-specific 
pericyte loss was observed in CM-ANG2-on mice (Figure 3, A and 
B, and Supplemental Figure 3A), skeletal muscle areas revealed 
Figure 3
Cardiomyocyte-specific ANG2 overexpression does not induce peripheral microcirculatory and hemodynamic alterations. (A and B) Cardiomyo-
cyte-specific ANG2 overexpression (CM-ANG2-on) reduces pericyte coverage (NG2 staining) of capillaries (PECAM-1 staining) in cardiac but not skel-
etal muscle (scale bar: 5 μm; n = 5). (C) Systemic mean arterial pressure (n = 6) and (D) LV developed pressure is normal in 24-week-old CM-ANG2-on 
mice (n = 6 per group). (E) CM-ANG2-on mice display normal LV end-diastolic diameter (n = 6). (F) Minimal fibrosis was detected in CM-ANG2-on 
hearts. Scale bars: 1,000 μm (Lens); 200 μm (×10); 50 μm (×40). (G) HW/BW ratio was unaffected in CM-ANG2-on mice (n = 6). *P < 0.05.
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Figure 4
EC-ANG2-on induced microcirculatory and hemodynamic alterations are antagonized by ANG1 and PDGFB. (A and B) Pericyte loss (NG2 
staining) and capillary rarefaction (PECAM-1 staining) in EC-ANG2-on mice are blocked by rAAV-transduced ANG1 and PDGFB, respectively 
(scale bar: 5 μm; n = 6 per group except PDGFB [n = 4]). (C and D) rAAV-transduced ANG1 and PDGFB normalized permeability in the ear 
vasculature of EC-ANG2-on mice (scale bar: 50 μm). (E) rAAV-transduced expression of ANG1 and PDGFB in 24-week-old EC-ANG2-on mice 
prevents an increase of LV end-diastolic diameter and (F) a reduction in HW/BW ratio in the case of PDGFB. n = 6 per group except EC-ANG2-on 
and PDGFB (n = 4). *P < 0.05, **P < 0.001.
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a normal ratio of pericyte/capillary cells (Figure 3B). Cardiac-re-
stricted ANG2 overexpression did not alter systemic blood pres-
sure (Figure 3C) or LV systolic function and diameter (Figure 3, D 
and E) over time. Consistently, no increase in fibrosis was found 
in hearts from this condition (Figure 3F and Supplemental Figure 
3B), and HW/BW ratio was normal in CM-ANG2-on mice (Figure 
3G). Wild-type hearts treated with cardiotropic rAAV at a dose 
transducing heart but not peripheral muscle phenocopied the 
hemodynamic results (Supplemental Figure 3, D–G, and Supple-
mental Methods). Thus, cardiomyocyte-specific ANG2 overex-
pression, though altering cardiac microvascular architecture, did 
not replicate the pan-endothelial EC-ANG2-on hypercirculatory 
state inducing cardiac remodeling.
A central mechanism of ANG2 signaling is to displace 
ANG1 from binding to the TIE2 receptor kinase, thereby 
altering endothelial/pericyte interaction, attachment to the 
extracellular matrix, and, consecutively, permeability (18, 19). 
In light of these properties, we devised two strategies to rescue 
the phenotype of ANG2-induced hypercirculatory cardiomyo-
pathy. First, we transduced mice with intravenous rAAV.ANG1 
injection, in order to restore the physiological ratio of ANG1 
and ANG2, albeit on a higher level (Supplemental Figure 4A). 
Second, we attempted to reattract pericytes to the capillaries, 
which had lost pericytes after ANG2 induction, via intrave-
nous injection of an rAAV-transducing PDGFB (Supplemental 
Figure 4B), an essential ligand for pericyte attraction (20). We 
found that rAAV.ANG1 and rAAV.PDGFB applied at 12 weeks 
of age both sufficed to increase the number of pericytes per 
mm2 of muscle area in heart muscle by 24 weeks of age (Figure 
4, A and B, and Supplemental Figure 4C). The normalization 
of the ANG1/ANG2 balance as well as restoration of pericyte 
coverage by PDGFB normalized permeability of ear capillaries 
in EC-ANG2-on mice (Figure 4, C and D). Moreover, cardiac 
enlargement (Figure 4E), indicating cardiac remodeling in 
EC-ANG2-on mice, was prevented after rAAV.ANG1 or rAAV.
PDGFB application. HW/BW ratios were significantly reduced 
by rAAV.PDGFB and displayed a strong trend toward reduction 
after rAAV.ANG1 transduction (P = 0.07; Figure 4F). In sum-
mary, forced expression of ANG1, which competes with ANG2 
for TIE2, and of PDGFB, which counteracts ANG2-induced 
pericyte loss, both efficiently block ANG2-induced microvas-
cular and hemodynamic disintegration.
The hyperpermeability and hypercirculatory state of the 
EC-ANG2-on mice, caused by disturbance of the peripheral micro-
circulation, bears strong resemblance to the cardiovascular altera-
tion found in sepsis. Therefore, we induced a systemic inflamma-
tion in wild-type mice and assessed the relevance of ANG2-induced 
pericyte loss and hyperpermeability for the hemodynamic destabi-
lization and mortality. i.p. injection of 20 mg/kg LPS sufficed to 
induce a robust upregulation of TNF-α and IL-6 (Figure 5, A and 
B). Pretreatment with a recombinant anti-ANG2 antibody, LC10, 
did not prevent the increase in levels of TNF-α and IL-6 seen in 
control antibody–treated animals (Figure 5, A and B). However, 
ANG2 antibody pretreatment blocked the LPS-induced permea-
bility increase of the ear vasculature (Figure 5C). Moreover, ANG2 
antibody application blunted the loss of pericytes observed in the 
early course of endotoxemia development (12 hours), both in the 
heart (Figure 5, D–F) as well as in peripheral muscles (Figure 5G), 
without significantly affecting neutrophil recruitment at this time 
point (Supplemental Figure 5A).
To assess the possibility that microvascular disintegration affects 
hemodynamic stability, causing septic shock, we analyzed the 
blood pressure in LPS-treated wild-type mice. Systemic hypoten-
sion, a hallmark of septic shock, was found at the same time point 
as microvascular disintegration (12 hours; data not shown) and 
persisted at 24 hours (Figure 5H). This hemodynamic alteration 
sufficed to inflict a high mortality rate, which progressed to 95% at 
36 hours. Anti-ANG2 antibody treatment with either of two differ-
ent antibodies, LC10 and LC06, was capable of reducing this rate 
significantly (Figure 5I). In contrast, EC-ANG2-on mice, which 
already displayed an edematous phenotype before LPS challenge, 
succumbed faster to the systemic inflammation than age-matched 
controls (Supplemental Figure 5B). A similar finding was obtained 
while applying LC10 in an alternate sepsis model inflicted by cecal 
puncture and ligation (Figure 5J). The observation that intra-
venous anti-ANG2 antibody application increased microvascular 
integrity, blood pressure, and survival points to a causative role of 
ANG2 for crucial microvascular alterations in sepsis.
Finally, we tested whether increasing the PDGFB level stabi-
lizes pericytes and thus antagonizes microvascular and hemody-
namic sequelae of endotoxemia. Pretreatment of wild-type mice 
with rAAV.PDGFB did not affect the level of inflammation (Sup-
plemental Figure 6A) but prevented the rise in vascular perme-
ability in the ear observed after LPS application (Supplemental 
Figure 6B). As hypothesized, pericyte loss was blunted by rAAV.
PDGFB in the coronary (Supplemental Figure 6, C and D) as well 
as in the peripheral microcirculation (Supplemental Figure 6E). 
Moreover, blood pressure was significantly higher than that in 
rAAV.LacZ-treated mice (Supplemental Figure 6F). Survival anal-
ysis revealed a better outcome in the case of rAAV.PDGFB at 24 
and 36 hours than after rAAV.LacZ pretreatment (Supplemen-
tal Figure 6G). Thus, PDGFB provides stabilization of pericyte 
attachment to the capillary network, a step sufficient to prevent 
increased permeability as well as hemodynamic dysregulation 
following septic stimulation.
Discussion
In this study, we found that increased endothelial ANG2 expres-
sion induces hyperpermeability and pericyte loss (Figure 1). In 
addition, EC-ANG2-on mice displayed a drop in systolic blood 
pressure (Figure 2, A and B), despite an increased cardiac out-
put (Figure 2D), indicating a hypercirculatory state. LV dilation, 
hypertrophy, and fibrosis were detected after 6 months of ANG2 
overexpression, reflecting compensatory cardiac remodeling 
(Figure 2, E–H). The notion that ubiquitous microvascular dis-
integration causes the hypercirculatory state was strengthened 
by the striking difference between the EC-ANG2-on and the 
CM-ANG2-on mouse strains, the latter displaying no apparent 
hemodynamic alterations despite cardiac pericyte loss (Figure 
3). The EC-ANG2-on phenotype was rescued by systemic appli-
cation of rAAV.ANG1 or rAAV.PDGFB, indicating that both 
TIE2 signaling and pericyte recruitment are of relevance for the 
EC-ANG2-on phenotype (Figure 4). These observations are rep-
licated by the in vitro analysis of pericyte recruitment to cultured 
endothelial cells, which is impaired after ANG2 transfection and 
rescued by ANG1 and PDGFB (Supplemental Figure 7).
The potential of ANG2 to disrupt vessel formation in the devel-
oping embryo was initially reported by Maisonpierre et al. (5). 
While in ANG2-transgenic E9.5 embryos a more severe lack of 
PECAM-1–positive cells is observed, the phenotype is qualitatively 
research article
3442 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013
Figure 5
Inhibition of ANG2 reduces pericyte loss and mortality in a sepsis model. (A) TNF-α and (B) IL-6 levels increase 12 hours after i.p. injection of 
LPS in control mice and mice treated with anti-ANG2 antibody (LC10). (C) LC10 treatment prevents increased microcirculatory permeability 12 
hours after LPS injection (representative result of n = 3). (D and E) LC10 treatment prevents pericyte loss and capillary rarefaction in coronary 
microcirculation. Scale bar: 100 μm (D); 5 μm (E). (F) Mice treated with ANG2 antibody (LC10) display increased capillary density (PECAM-1 
staining) and pericyte coverage (NG2 staining) in myocardial and (G) peripheral microcirculation of quadriceps muscle (n = 5 per group). (H) 
Mean blood pressure after 12 hours (n = 10 per group) and (I) survival were increased following sepsis induction in mice pretreated with ANG2 
antibodies (n = 25 for Control-Ab, n = 23 for LC10, n = 13 for LC06; log-rank P = 0.0044 for LC10, P = 0.017 for LC06). (J) LC10 treatment is 
able to reduce mortality in a cecal ligation and puncture model of sepsis (n = 22 for Control-Ab, n = 21 for LC10; log-rank P = 0.036). *P < 0.05.
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Interestingly, the close connection of microvascular integrity and 
blood pressure homeostasis has also been observed in Pdgfbret/ret trans-
genic mice. Here, a variant lacking the retention motif of PDGFB 
required for association with extracellular matrix causes a similar 
phenotype: besides pericyte loss (35) and capillary rarefaction, car-
diac output and heart weight increased, indicating a hypercirculatory 
state (36). In the EC-ANG2-on strain, which did not display altered 
PDGFB expression in heart and muscle tissue (Supplemental Figure 
2F), hyperpermeability and cardiac remodeling were prevented by 
using a long-lasting rAAV.PDGFB vector, which recruited pericytes 
to capillaries (Figure 4). Consistently, an rAAV.PDGFB vector was 
capable of blunting mortality during LPS-induced systemic inflam-
mation, similar to anti-ANG2 antibodies (Supplemental Figure 6). 
These findings support the role of pericytes for control of vascular 
permeability and hemodynamic stability.
In summary, pan-endothelial ANG2 overexpression induces a pro-
found phenotype, featuring hyperpermeability and pericyte loss as 
well as hypercirculatory hypotension, subsequently leading to car-
diac hypertrophy and fibrosis. These alterations were prevented by 
increasing ANG1, an antagonist of ANG2, or by PDGFB, providing 
pericyte recruitment. Moreover, ANG2 inhibition and PDGFB over-
expression significantly reduced microvascular alterations as well 
as hypotension and mortality in LPS-induced systemic inflamma-
tion. Thus, ANG2-induced pericyte loss exerts a causative role in the 
hemodynamic alterations, culminating in septic shock and making 
ANG2 a worthwhile therapeutic target in these pathologies.
Methods
Transgenic mice. Transgenic mice were generated following standard pro-
cedures described previously (37). We used the endothelial cell–specific 
tetracycline-regulatable transactivator transgenic (activator) mouse line, 
B6JTg(TIE2-tTA)3Udeu (TIE2-tTA) (38), and a responder mouse line carry-
ing a chicken β-globin insulator flanked bidirectional construct coding for 
hANG2 and a GFP reporter, B6J-Tg(TRE-hANG2)5Udeu (TRE-hANG2) 
(Supplemental Figure 1A). Breeding stock for generation of double trans-
genic mice was kept on doxycycline-containing food until pups were deliv-
ered. Then, endothelial cell–specific expression of hANG2 (EC-ANG2-on; 
Supplemental Figure 1) was induced by stopping the feeding of doxycy-
cline at birth in all groups (doxycycline [Sigma-Aldrich]; 100 mg/kg chow). 
In a subgroup (EC-ANG2-off), doxycycline was reapplied from 12 to 24 
weeks of age, terminating the transgenic overexpression. In double trans-
genic mice of the Tg(TRE-hANG2)5Udeu line, no expression of GFP is 
detectable from the bidirectional construct in the absence of doxycycline. 
Mice were housed under specific pathogen–free conditions in either indi-
vidually ventilated or filter top cages. The genotype of mice was confirmed 
by PCR using tail biopsies before and after the experiments. Alternately, 
an α-MHC-tTA activator line (FVB.Cg-Tg [Myh6-tTA]6Smbf/J; The Jack-
son Laboratory) was used to generate double transgenic mice expressing 
hANG2 in a cardiomyocyte-restricted fashion in the absence of tetracycline 
(CM-ANG2-on mice) (39).
For analyses, double transgenic mice were compared with single trans-
genic littermate control animals (off doxycycline). All animal procedures 
were performed in accordance with the animal protection law of the Kan-
ton Bern, Switzerland, the Swiss legislation on the protection of animals, 
and approved by the respective government authorities.
Genotyping. Offspring from matings of hemizygous TIE2-tTA and 
TRE-hANG2 mice were biopsied at weaning age, and tissue lysates were 
analyzed by PCR for the presence of the respective transgenes. Primers 
(hANG2 FW3 [5′-TGCCACGGTGAATAATTCAG-3′] and hANG2 REV3 
[5′-TTCTTCTTTAGCAACAGTGGG-3′]) were used for the TRE-hANG2 
similar to that of the EC-ANG2-on mice in our study (Figure 1, 
E–G). Capillary regression and pericyte loss are also present in our 
endotoxemia model 12 hours after LPS injection (Figure 5), indi-
cating that microcirculatory disruption is a cause for the hyper-
permeable and hypercirculatory state. ANG2 levels are increased 
in this state and have been established as a prognostic biomarker 
for identification of the patient group with the highest mortal-
ity rates (21). Although antagonism of ANG2, e.g., by increasing 
ANG1 levels, has been performed successfully in sepsis (22, 23), we 
could show a significant effect of ANG2 inhibition for survival in 
endotoxemia/sepsis for the first time. In our study, the anti-ANG2 
antibody did not attenuate the overall level of inflammation and 
endothelial activation in a model of LPS-induced endotoxemia 
(Figure 5, A and B, and Supplemental Figure 5A), as opposed 
to other antiinflammatory strategies directly affecting the LPS/
TLR4–mediated signaling pathways, such as hepcidin (24).
At first sight, a contradictory result comes from Tzepi and 
coworkers, who reported that hANG2 pretreatment attenuated 
liver TNF-α secretion upon Pseudomonas aeruguinosa infection, 
providing a survival advantage, which was not reproduced in 
TNF-α–deficient mice. However, ANG2 pretreatment did not pro-
vide a survival advantage after LPS treatment, rather revealing a 
trend toward lower survival (25). Moreover, in the study by Tzepi 
et al., pretreatment with 25 μg/kg human recombinant ANG2 was 
exogenously applied, differing from our strategy of inhibition of 
endogenous ANG2 activity upon LPS endotoxemia (Figure 5I). It 
is noteworthy that chronic ANG2 upregulation in the EC-ANG2-
on mice further decreased survival after LPS endotoxemia in our 
study (Supplemental Figure 5B), pointing to a potential difference 
of chronic versus acute ANG2 upregulation.
The impact of ANG2 on the hemodynamic status required 
pan-endothelial exposure such as in the EC-ANG2-on model (Fig-
ure 2) and was absent in cardiac-restricted ANG2-overexpressing 
mice (Figure 3). Earlier studies demonstrated that ANG2 release 
from Weibel-Palade bodies is induced by increased endothelial 
stretch, which occurs during hypertension (26), potentially counter-
acting the hypertensive alterations. Accordingly, previous work by 
Reiss and coworkers suggests that ANG2 overexpression also affects 
smooth muscle cell recruitment directly or indirectly (via disturbed 
microvessel maturation) in a murine hind limb ischemia model 
(27). Recent evidence points to the possibility of a direct effect of 
pericytes on the vascular tone, e.g., after traumatic brain injury (28).
Of note, nitric oxide synthase inhibition by oral l-NAME applica-
tion was also capable of entirely preventing hypotension and sub-
sequent cardiac remodeling of the EC-ANG2-on phenotype (mean 
arterial pressure 100 ± 8 mmHg vs. 84 ± 3 mmHg in the EC-ANG2-
on group, HW/BW ratio 4.82 ± 0.14 vs. 7.21 ± 1.10 in the EC-ANG2-
on group). Nitric oxide release upon VEGF-A stimulation (29, 30) 
mediates microvascular permeability (31) and hypotension (32). 
Ahmed et al. reported that a single administration of an adenovirus 
encoding for ANG2 reduces atherosclerosis progression in Apoe–/– 
mice fed with Western diet, an effect blocked by nitric oxide syn-
thase inhibition (33). Thus, nitric oxide and ANG2 signaling display 
several functional similarities. However, recruitment of mural cells 
(pericytes and smooth muscle cells) after induction of murine hind 
limb ischemia requires nitric oxide (34), whereas in our study, ANG2 
mediates endotoxemia-induced loss of pericytes (Figure 5, D–G). 
This difference may either be related to varying pathophysiologic 
stimuli (ischemia vs. endotoxemia) or imply an alternate behavior 
of pericytes upon ANG2 or nitric oxide stimulation.
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dard cesium sedimentation as previously described (43). Viral titers were 
determined using real-time PCR against the bGH 3′-untranslated region 
of the virally encoded transcript. The forward primer sequence was 
5′-TCTAGTTGCCAGCCATCTGTTGT-3′, and the reverse primer sequence 
was 5′-TGGGAGTGGCACCTTCA-3′. Trans and helper plasmids were pro-
vided by James M. Wilson, University of Pennsylvania, Philadelphia, Penn-
sylvania, USA. Real-time PCR was used for virus detection in transfected 
mouse tissue. Primer sequences for human ANG1 mRNA were forward 
5′GGCCACAAGCATCAAACCAC and reverse 5′AATGGACTGGGAAGG-
GAACC; primer sequences for human PDGFB mRNA were forward 5′CCT-
CATAGACCGCACCAA and reverse 5′CGCACAATCTCGATCTTTCT; 
primer sequences for ANG2 were forward 5′TAGCATCAGCCAACCAG-
GAA and reverse 5′TAGTACTGTCCATTCAAGTT; and primer sequences 
for GAPDH were forward 5′ACCAGGAAATGAGCTTGACA and reverse 
5′TCTTGGGCTACACTGAGGAC. Real-time PCR was performed using 
SYBR Green (Bio-Rad) for 40 cycles (30 seconds at 95°C, 30 seconds at 
58°C, 30 seconds at 72°C) in an iQ-Cycler (Bio-Rad).
ANG2 antibody generation. Binding domains of the anti-ANG2 antibodies 
LC10 (RO5485202) and LC06 (RO5314193) were obtained from human 
antibody libraries, and the obtained VH and VL regions were maturated 
and then fused to the constant part of a human IgG1 antibody. The desired 
genes were generated by gene synthesis (GeneArt), PCR amplified, and 
cloned into suitable expression vectors. Variants of expression plasmids 
for transient expression in the HEK293-F system (Invitrogen) were applied 
for the expression of the described antibodies.
In order to study the effects of ANG2 and the respective antibodies on 
TIE2 downstream signaling, we have generated a HEK293 clone stably 
transfected with human TIE2. Stimulation with ANG2 or ANG1 results 
in phosphorylation of TIE2 in these cells. Subsequently, the ability of the 
identified antibodies to interfere with ANG2- and ANG1-mediated TIE2 
phosphorylation was examined. LC06 has been described previously (44). 
LC10 showed a dose-dependent interference with ANG2-stimulated TIE2 
phosphorylation, with an EC50 value of 3 nM. There was no interference 
with ANG1-stimulated TIE2 phosphorylation.
To further assess the selectivity of the ANG2 antibody, surface plas-
mon resonance was used. The Fab of RO5485202 was immobilized on 
the surface of a C1 SPR Chip. Fixed concentrations of hANG2 (multi-
meric) were preincubated together with increasing concentrations of 
the corresponding (immobilized) antibody and injected onto the flow 
cells. The Kd was calculated by plotting the concentrations of free hANG2 
against the antibody concentrations (affinity in solution). The SPR data 
showed 10 nM affinity of RO5485202 for human and mouse ANG2 and 
no binding to human and mouse ANG1, confirming the selectivity of the 
antibody for ANG2.
Histological analysis and ELISA. Organs for histological analysis were embed-
ded in Tissue-Tek OCT Compound (Sakura Finetek), and 8-μm sections were 
prepared using a cryotome. Sections were fixed with 4% paraformaldehyde 
and afterward blocked with 3% bovine serum albumin 0.1% Triton-X in 
PBS for 1 hour at room temperature. Primary antibodies used were CD31/
PECAM-1 (BD Biosciences) and NG2 (Millipore). After washing with PBS, 
sections were incubated in appropriate fluorescent secondary antibodies 
(1:500) in PBS for 1 hour at room temperature. ELISAs from blood samples 
were performed using Quantikine ELISA Kits for murine IL-6 (R&D Systems) 
and murine TNF-α (R&D Systems) according to the respective protocols.
Statistics. Data are given as mean ± SEM. Differences among several 
groups were tested using ANOVA and Student Newman Keul’s post-hoc 
analysis. P < 0.05 was considered statistically significant. Differences in 
survival curves were analyzed with the log-rank test (Kaplan-Meier sur-
vival). All data were assessed using the SPSS software package (version 20.0; 
http://www.spss.com).
allele PCR, with 35 cycles of 30 seconds at 94°C, 30 seconds at 54°C, and 
30 seconds 72°C. The resulting PCR product was 150 bp in size. For both 
tTA transgenic alleles, a product of 535 bp in size was amplified by 35 
cycles of 30 seconds at 94°C, 45 seconds at 63°C, and 45 seconds at 72°C, 
using the primers tTA-FW2 (5′-GACGCCTTAGCCATTGAGATG-3′) and 
tTA-Rev2 (5′-CAGTAGTAGGTGTTTCCCTTTCTTC-3′).
Chronic mouse protocol. At 12 weeks of age, EC-ANG2-on mice, CM-ANG2 
on mice, and controls underwent baseline assessment of echocardiographic 
imaging using a standard ultrasound system combined with a 15 MHz trans-
ducer (Acuson Sequoia 512 and Acuson 15L8 Transducer, Siemens AG), and 
noninvasive blood pressure was measured using the CODA system (Kent Sci-
entific). Thereafter, EC-ANG2-on mice were treated with doxycycline, rAAV.
PDGFB (5 × 1012 virus particles), or rAAV.ANG1 virus (5 × 1012 virus parti-
cles) where indicated. An additional group of C57BL/6 mice received 1 × 1012 
virus particles in the tail vein for cardiomyocyte-specific transduction (Sup-
plemental Figure 3, D–G, and Supplemental Methods). Echocardiographic 
imaging was repeated at 18 and 24 weeks followed by a LV catheterization 
using a Millar-Tip catheter (SPR-671, Millar Instruments) to determine the 
LV developed pressure and LV end-diastolic pressure (40). For evaluation of 
pressure-volume relationships, an impedance-micromanometer catheter 
(Millar Instruments) was placed the same way, and pressure-volume loops 
were recorded (41). Raw conductance volumes were corrected for parallel 
conductance by the hypertonic saline dilution method.
Sepsis protocol. C57BL/6J mice (Charles River) were injected with anti-
ANG2 antibody (LC10 or LC06, Roche, 20 mg/kg i.p.) or a control anti-
body (AP112, Millipore, 20 mg/kg i.p.) 24 hours before induction of 
the systemic inflammation using 20 mg/kg LPS from E. coli (L2880, 
Sigma-Aldrich). The scoring system used to assess the clinical severity is 
described in Supplemental Table 1. Endotoxemia severity was assessed as 
described above at 6, 12, 24, and 36 hours in a blinded fashion. A score of 
20 or higher was equated with the death of the animal. Noninvasive blood 
pressure was measured at 12 and 24 hours as outlined above. Blood plasma 
samples were taken at 12 hours, and permeability was assessed at 6 hours 
after induction of systemic inflammation (see below).
For cecal ligation and puncture, C57BL6/J mice were pretreated with 
20 mg/kg antibody i.p. 24 hours prior to ligation of 1 cm of cecum fol-
lowed by 3 punctures (23-gauge needle).
Permeability measurement. Multiphoton microscopy was performed with a 
TriMScope (LaVision BioTec) in single point scanning mode. 860 nm wave-
lengths were used to simultaneously excite TRITC fluorescence (recorded 
with 580/60-nm filter) and second harmonic generation of collagen 
(447/60-nm filter) (42). In analgosedation (see above), a mouse ear region 
was placed perpendicular to the optical axis on the microscopic stage. A 
suitable area of the ear was roughly localized by 1-photon background 
fluorescence and precisely defined using the second harmonic generation 
signal. A 3D movie was recorded, with a 200- × 200- × 36-μm stack (10 
planes with 534 pixels squared each) being recorded every 15 seconds for 
5 minutes. After recording the first data point, 750 μg TRITC-dextrane, 
with a molecular weight of 4 kDa (T1037, Sigma-Aldrich), was injected in 
150 μl PBS. For data analysis, 3 areas were marked in direct contact to the 
vessel with an average size of 100 μm2, and mean gray values (MGVs) were 
recorded in every picture using ImageJ imaging software (W.S. Rasband, 
US National Institutes of Health, http://imagej.nih.gov/ij/). Extravascular 
fluorescence at the time point of maximal intravascular fluorescence (in 3 
different measurements after an average of 15 to 45 seconds after injection 
of TRITC-dextrane) was set as the starting point for the measurement and 
defined as 100% extravascular fluorescence. Changes in MGVs over time 
were calculated as the percentage of MGV at the starting point.
Virus production. The rAAV.hANG1, rAAV.hPDGFB, rAAV.hANG2, and 
rAAV.LacZ vectors were produced in U293 cells and purified with stan-
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